29 June 2016

Virotec teams up with TerraPlus

13/11/01

Aim-listed green technology firm Virotec has signed an important Memorandum of Understanding with Iberian-based engineering consultant TerraPlus, writes James Crux.

Formerly listed as a mining venture Down Under, Virotec (VTI) has worldwide marketing and distribution rights to Bauxsol, a 'green' technology that neutralises acid and removes heavy metals from environmentally contaminated water.

Recent estimates suggest that the market for the technology could be worth 100 billion. In today's announcement, the Virotec board said that engineering consultant TerraPlus had 'already identified potential opportunities in the Portuguese and Spanish mining industries' to use Virotec's Bauxsol technology. TerraPlus full name TerraPlus Engenharia Do Ambiente E Fiscalizacao LDA has a strong presence in the civil engineering, mineral extraction, water management and sanitation services fields. Under the terms of the MOU, TerraPlus will be Virotec's exclusive licensed agent in Portugal and a non-exclusive licensed agent in Spain, with Virotec supplying the actual Bauxsol technology as well as technical support, on a project-by-project basis.

Today's news appears to be a significant strategic development for the company. At a recent meeting with journalists, executive chairman Brian Sheeran said that 'our aim is not only to protect the environment, but to do it in an economically appealing way that will save mining companies money. We came to Aim to internationalise the technology and be first to market'. In line with this strategy, Virotec recently opened up an Italian subsidiary, Virotec Italia, operating from Rome. The Italian office is working to secure permits and licences for the transportation and application of its Bauxsol technology across the European Union, while other offices will be opened across Europe.

The chemicals-listed company floated on Aim in July following a placing of 27.5 million new shares at 14p, which raised 3.36 million net. The shares were unchanged at 15.75p on today's news, valuing the business at 21.65 million.

Cash Shells 2015

Published in September 2015 this annual research report provides a comprehensive overview of cash shells on the Main Market, AIM and PLUS landscape. Order your copy today

 

Superb investment toolkit for private investors

SharePad is the new web-based service from ShareScope. Easier to use and more powerful. Perfect for tablets, Macs and Windows PC. Covers ALL your investment requirements.

Growth Company Investor: free trial

Since 2008, our share tips outperformed the benchmark by 281%. Take a free trial and get access to our recommendations today. Start free trial now.

Directors' Pay on AIM 2015

The most comprehensive review of AIM directors' pay available, and this year includes a record sample of 1000+ AIM-quoted companies. The full report is available to order for £385 + VAT. Click here for more info

 

Latest small-cap and growth company news

Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.

Popular News

Latest News

Omega investing in growth 28/06/16

Omega Diagnostics results looked positive and highlighted the progress being made in getting important new products to market. The investment to support those efforts will depress profits this year; but the market seems willing to look through this with Omega being a rare stock to be trading above its pre-Brexit level.

Stadium hit by profit warning 23/06/16

Stadium Group shares have been hit by a profit warning. This is a particular blow given the company’s progress in repositioning itself into a higher quality, design-led business.

Verona raises £42m to fund drug trials  19/06/16

Verona Pharma (AIM: VRP) has raised an impressive £42 million net of costs which will fund phase II trials for its RPL554 compound. This drug targets severe respiratory diseases, in particular the 65 million worldwide sufferers from COPD (chronic obstructive pulmonary disease).

Income attractions at Belvoir 15/06/16

It’s fair to say that buy-to-let landlords have been under George Osborne’s cosh. He’s introduced a raised stamp duty rate and withdrawn higher-rate tax relief. However, Belvoir Lettings has seen little change in the market as far as its core lettings agency business is concerned. Furthermore, the shares have responded positively to a major acquisition which makes Belvoir the largest UK lettings agent.

Wincanton keeps on trucking 12/06/16

Wincanton CEO Adrian Colman feels his company is now back on an even keel after a period of fire-fighting. Debt has been brought under control, the pension deficit is being addressed, and onerous leases and contracts have been dealt with. A return to the dividend list illustrates these positive changes and the fact that management can now fully focus on growing the business.

VP maintains its reputation for quality   09/06/16

Plant hire company VP continues to perform well against a mixed backdrop. Management said that the core infrastructure, housing and construction markets remained generally supportive and have offset weakness in oil and gas.

More News